Core Viewpoint - Hualan Biological Engineering has intensified its strategy in AI-driven pharmaceuticals by expanding its AI Medical Expert Committee and electing new members, indicating a commitment to leveraging AI in drug development [1][2] Group 1: Company Developments - Hualan Biological announced the addition of Hu Tony Ye to its AI Medical Expert Committee, enhancing the committee's expertise with his extensive background in biomedical engineering and industry connections [2] - The company plans to invest 20 million yuan in Suzhou Kema Biotechnology, which is expected to benefit from the technological integration of its shareholders and Hualan's extensive client network [1][2] Group 2: Market Outlook - Huatai Securities forecasts a significant growth in the global AI-enabled drug development market, projecting an increase from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate of 22.6% [3] - The report highlights that Hualan's core business is expected to maintain growth, particularly in its cartridge business, with revenue growth projected between 5% and 15% [3] Group 3: Financial Projections - Huatai Securities has raised its target price for Hualan from 39.46 yuan to 69.60 yuan, maintaining a "buy" rating based on the company's growth potential in AI pharmaceuticals and ongoing order fulfillment [4]